

# FINAL PROGRAM



# XIX NIBIT Virtual Meeting

Cancer immunity and immunotherapy  
beyond COVID-19



October 14-15, 2021


[www.nibit.org](http://www.nibit.org)



UNDER THE AUSPICES OF:



ASSOCIAZIONE ITALIANA ONCOLOGIA TORACICA



## ACKNOWLEDGMENTS:



Una Divisione Pierre Fabre Pharma

# NIBIT SCIENTIFIC COMMITTEE AND FACULTY

## SCIENTIFIC COMMITTEE

**Paolo Ascierto** (Napoli, Italy)  
**Matteo Bellone** (Milano, Italy)  
**Vincenzo Bronte** (Verona, Italy)  
**Mario Paolo Colombo** (Milano, Italy)  
**Pier Francesco Ferrucci** (Milano, Italy)

**Marina Garassino** (Chicago, USA)  
**Paola Nisticò** (Roma, Italy)  
**Antonio Rosato** (Padova, Italy)  
**Vincenzo Russo** (Milano, Italy)  
**Antonio Sica** (Novara, Italy)

## FACULTY

**Paolo Ascierto** – Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” (Napoli, Italy)  
**Matteo Bellone** – IRCCS Ospedale San Raffaele (Milano, Italy)  
**Chiara Bonini** – IRCCS Ospedale San Raffaele (Milano, Italy)  
**Vincenzo Bronte** – Università degli Studi di Verona (Verona, Italy)  
**Federico Cappuzzo** – IFO Istituto Regina Elena (Roma, Italy)  
**Marco Cassatella** – Università degli Studi di Verona (Verona, Italy)  
**Triantafyllos Chavakis** – Universitätsklinikum Carl Gustav Carus (Dresden, Germany)  
**Rita Chiari** – Ospedali Riuniti Padova Sud “Madre Teresa di Calcutta” (Padova, Italy)  
**Paola Chiarugi** – Università degli Studi di Firenze (Firenze, Italy)  
**Mario Paolo Colombo** – IRCCS Istituto Nazionale dei Tumori (Milano, Italy)  
**Ruggero De Maria** – IFO Istituto Regina Elena (Roma, Italy)  
**Lucia Del Mastro** – Università di Genova (Genova, Italy)  
**Alexander M.M. Eggermont** – UMCU Utrecht University (Utrecht, The Netherlands)  
**Pier Francesco Ferrucci** – Istituto Europeo di Oncologia IEO (Milano, Italy)  
**Bernie Fox** – Oregon Health & Science University (OHSU) (Portland, USA)  
**Wolf-Herman Fridman** – Université Paris Descartes (Paris, France)  
**Dmitry Gabrilovich** – AstraZeneca  
**Enzo Galligioni** – Fondazione Pezcoller (Trento, Italy)  
**Marina Garassino** – University of Chicago (Chicago, USA)  
**Sharam Kordasti** – King’s College London (London, UK)  
**Massimiliano Mazzone** – VIB KU Leuven Center for Cancer Biology (Leuven, Belgium)  
**Kathy McCoy** – University of Calgary (Calgary, Canada)  
**Miriam Merad** – Mount Sinai Human Immune Monitoring Center (HIMC) (New York, USA)  
**Rita Nanda** – University of Chicago (Chicago, USA)  
**Mihai G. Netea** – Radboud University Medical Center (Nijmegen, The Netherlands)  
**Paola Nisticò** – IFO Istituto Regina Elena (Roma, Italy)  
**Renato Ostuni** – IRCCS Ospedale San Raffaele (Milano, Italy)  
**Nicholas P. Restifo** – National Cancer Institute - NIH (Bethesda, USA)  
**Antonio Rosato** – Università degli Studi di Padova (Padova, Italy)  
**Vincenzo Russo** – IRCCS Ospedale San Raffaele (Milano, Italy)  
**Angela Santoni** – Sapienza Università di Roma (Roma, Italy)  
**Catherine Sautes-Fridman** – UPMC Sorbonne Université (Paris, France)  
**Antonio Sica** – Università del Piemonte Orientale (Novara, Italy)  
**Claudio Tripodo** – Università degli Studi di Palermo (Palermo, Italy)  
**Shannon Turley** – Cancer Immunology, Genentech (San Francisco, USA)  
**Ivan Zanoni** – Boston Children’s Hospital (Boston, USA)  
**Roberta Zappasodi** – Weill Cornell Medicine (New York, USA)

# FINAL SCIENTIFIC PROGRAMME

THURSDAY, OCTOBER 14


11:30	NIBIT Assembly
13:00	Registration and connection
13:45	Welcome addresses

## SESSION 1 WHAT'S NEW IN CANCER IMMUNOTHERAPY

NIBIT-AIOM JOINT SESSION

Discussants: **Paolo Ascierto, Rita Chiari, Lucia Del Mastro, Wolf-Herman Fridman**

14:00	<b>Silent Poster Trailer A</b>
14:10	<b>Alexander Eggermont</b> (Utrecht, The Netherlands) <i>The IO revolution in melanoma: lessons from advanced disease into neo-adjuvant strategies</i>
14:30	<b>Chiara Bonini</b> (Milan, Italy) <i>Engineered T cells for the treatment of hematological malignancies</i>
14:50	<b>Federico Cappuzzo</b> (Rome, Italy) <i>Update on immunotherapy in lung cancer</i>
15:10	<b>Rita Nanda</b> (Chicago, USA) <i>The current and emerging role of immunotherapy in breast cancers</i>
15:30	<b>News from the companies: Stefan Eulitz</b> (Miltenyi Biotec) <i>MACSima™ ultrahigh-content imaging helps to identify CAR target candidates</i>
15:37	Discussion
16:00	End of Session 1



## THURSDAY, OCTOBER 14

---

### SESSION 2 ADAPTIVE AND TRAINED IMMUNITY IN HEALTH AND CANCER

NIBIT- SIICA JOINT SESSION


Discussants: **Marco Cassatella, Renato Ostuni, Angela Santoni, Catherine Sautes-Fridman**

16:10	<b>Silent Poster Trailer B</b>
16:20	<b>Mihai G. Netea</b> (Nijmegen, The Netherlands) <i>Trained immunity: from biology to therapeutic target</i>
16:40	<b>Triantafyllos Chavakis</b> (Dresden, Germany) <i>Trained innate immunity and Trained granulopoiesis in cancer</i>
17:00	<b>Miriam Merad</b> (New York, USA) <i>Mapping macrophage and dendritic cell functional diversity in lung cancer lesions</i>
17:20	<b>Claudio Tripodo</b> (Palermo, Italy) <i>Expression of TCR recombinase/revision machinery in the tumor microenvironment hints and the rising immune pressure</i>
17:40	Selected Abstract <b>Gaetano Finocchiaro</b> (Milano, Italy) <i>TEM-GBM: A phase I-IIa clinical study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme</i>
17:50	Discussion
18:05	End of Session 2

### GIORGIO PARMIANI KEYNOTE LECTURE

Chairman: **Pier Francesco Ferrucci**

18:15	<b>Bernie Fox</b> (Providence, USA) <i>Translation: An Iterative and Team Process – Our Path to the Development of Triplet Cancer Immunotherapy.</i>
-------	---



## FRIDAY, OCTOBER 15

### POSTER SESSION 1

Discussants: **Federica Benvenuti, Silvia Piconese, Antonio Rosato**

09.00	<b>Arianna Brevi</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>Castration-related remodeling of the tumor microenvironment supports signaling through integrin α2 and progression to neuroendocrine prostate cancer</i>
09.10	<b>Caterina Cascini</b> – IRCCS Istituto Nazionale dei Tumori (Milano, Italy) <i>The transcription factor ZEB1 shapes osteosarcoma aggressiveness by affecting tumour cell differentiation and stemness features</i>
09.20	<b>Francesco Cilenti</b> – Università Vita-Salute San Raffaele (Milano, Italy) <i>A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression</i>
09.30	<b>Alessia Melacarne</b> – Humanitas Research Hospital (Rozzano – MI, Italy) <i>Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides</i>
09.40	<b>Silvia Mola</b> – Università del Piemonte Orientale “A. Avogadro” (Vercelli, Italy) <i>The protein TRIM28 as a key connector between chronic inflammation and carcinogenesis</i>
09.50	<b>Celeste Rizzello</b> – IRCCS Istituto Nazionale dei Tumori (Milano, Italy) <i>Osteopontin protects from autoimmunity-driven diffuse large B cell lymphoma development</i>
10.00	<b>Roberto Ruiu</b> – Università degli Studi di Torino (Torino, Italy) <i>Role of the cystine/glutamate antiporter xCT in the interaction between mammary cancer and the immune system</i>

### POSTER SESSION 2

Discussants: **Arianna Calcinotto, Claudia Chioldoni, Antonio Sica**

10.15	<b>Michela Consonni</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia</i>
10.25	<b>Antonino Di Lorenzo</b> – Università degli Studi di Torino (Torino, Italy) <i>Targeting the crosstalk between TLR2 and the cystine/glutamate antiporter xCT as a new combined therapy for breast cancer</i>
10.35	<b>Lorena Maria Ferreira</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>Steady IFNα therapy prevents the development of colorectal cancer liver metastases through the activation of liver sinusoidal endothelial cells</i>
10.45	<b>Irene Fischetti</b> – IRCCS Istituto Nazionale dei Tumori (Milano, Italy) <i>Concomitant targeting of AR and EZH2 synergistically reduces immunosuppression and induces regression of castration resistant prostate cancer</i>
10.55	<b>Marinos Kallikourdis</b> – Humanitas Research Hospital (Rozzano – MI, Italy) <i>T cells as drivers of Immune Checkpoint Inhibitor Tumor Immunotherapy-induced cardiotoxicity</i>
11.05	<b>Lucía López</b> – ICGEB - International Centre for Genetic Engineering and Biotechnology (Trieste, Italy) <i>Boosting type 1 DCs activity enhances PD-L1 blockade in mismatch repair deficient lung tumors</i>
11.15	<b>Gloria Delfanti</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>Dual targeting of cancer and suppressive myeloid cells by tumor-redirected iNKT cells and antigen-carrying microparticles</i>

---

### POSTER SESSION 3


Discussants: **Paola Allavena, Pier Francesco Ferrucci, Paola Nisticò**

11.30	<b>Sara Bruschini</b> – Azienda Ospedaliero-Universitaria Sant'Andrea (Roma, Italy) <i>Dissecting the tumour immune microenvironment of advanced NSCLC</i>
11.40	<b>Emilia Cocorocchio</b> – Istituto Europeo di Oncologia (Milano, Italy) <i>Primary Ipilimumab/Nivolumab immunotherapy followed by adjuvant Nivolumab in patients with locally advanced or oligometastatic melanoma</i>
11.50	<b>Roberta Melchionna</b> – IRCCS Regina Elena National Cancer Institute (Roma, Italy) <i>hMENA regulates TGF-β signaling and affects CAF-Cancer cell-T cell dialogue in NSCLC</i>
12.00	<b>Angeli D. Macandog</b> – Istituto Europeo di Oncologia (Milano, Italy) <i>Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with response</i>
12.10	<b>Filippo Pederzoli</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>The role of gut microbiota and its perturbation by antibiotics in mediating response to neoadjuvant pembrolizumab in muscle invasive urothelial carcinoma of the bladder</i>
12.20	<b>Alessia Potenza</b> – IRCCS Ospedale San Raffaele (Milano, Italy) <i>CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve adoptive T cell therapy for colorectal cancer</i>
12.30	<b>Anna Tosi</b> – Università degli Studi di Padova (Padova, Italy) <i>The immune cell landscape of metastatic uveal melanoma correlates with overall survival</i>

12:40

**VIRTUAL POSTER WALK**

13:30



## FRIDAY, OCTOBER 15


---

### SESSION 3 **METABOLISM AT THE INTERSECTION BETWEEN CANCER AND IMMUNITY**

NIBI-SIC JOINT SESSION

Discussants: **Paola Chiarugi, Antonio Rosato, Vincenzo Russo, Ivan Zanoni**

14:00	<b>Marina Garassino</b> (Chicago, USA) <i>Obesity and ICB</i>
14:20	<b>Antonio Sica</b> (Novara, Italy) <i>Multitargeting of protumor myelopoiesis</i>
14:40	<b>Roberta Zappasodi</b> (New York, USA) <i>Targeting Treg metabolism to improve cancer immunotherapy</i>
15:00	<b>Dmitry Gabrilovich</b> (AstraZeneca, USA) <i>Metabolism and regulation of myeloid-derived suppressor cells</i>
15:20	Selected Abstract <b>Teresa Manzo</b> (Milano, Italy) <i>Lipid-instructed metabolic rewiring unleash the anti-tumor potential of CD8 T cells</i>
15:30	Discussion
15:50	End of Session 3



## FRIDAY, OCTOBER 15

### SESSION 4 TARGETING IMMUNE-RELATED TUMOR CELL-EXTRINSIC MECHANISMS

NIBIT-ACC JOINT SESSION


Discussants: **Matteo Bellone, Vincenzo Bronte, Ruggero De Maria, Paola Nisticò**

16:00	<b>Massimiliano Mazzone</b> (Leuven, Belgium) <i>Harnessing tumor metabolism to overcome immunosuppression: a novel way to enhance the success of cancer immunotherapy</i>
16:20	<b>Kathy McCoy</b> (Calgary, Canada) <i>Microbes and Metabolites in Regulating Immune Function</i>
16:40	<b>Shannon Turley</b> (San Francisco, USA) <i>Stromal evolution in tumor progression and response to immunotherapy</i>
17:00	<b>News from the companies: Sharam Kordasti</b> (London, UK) <i>Tregs as "inflammo-meter" in myeloid malignancies</i>
17:20	Selected Abstract <b>Laura Lucia Cogrossi</b> (Milano, Italy) <i>Intestinal microbiota modulates dendritic cell function in the bone marrow and impacts disease progression in mice affected by multiple myeloma</i>
17:30	Discussion
17:50	NIBIT Career Award

### PEZCOLLER KEYNOTE LECTURE

Chairman: **Mario Paolo Colombo**

18:00	<b>Enzo Galligioni</b> (Trento, Italy) <i>The Pezcoller Foundation</i>
18:05	<b>Nicholas P. Restifo</b> (Bethesda, USA) <i>An engineered IL-2 partial agonist promotes CD8+ T cell stemness</i>
18:50	NIBIT Awards Election results
19:10	<b>Adjourn</b>



## NIBIT USEFUL INFORMATION

If you wish to become a member of NIBIT Association, please visit

[https://www.nibit.org/iscrizioni\\_nibit.php](https://www.nibit.org/iscrizioni_nibit.php)

The rate is € 50,00 / year

## ORGANISING SECRETARIAT



**Acheloís - Professional Congress Organiser**

Via Larga 8 - 20122 Milano

Tel. 02 2643 6227

e-mail: linda.isella@achelois.eu

ACHELOÍS - Professional Congress Organiser

